Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

    5 Reasons Why Merck (MRK) is a Good Stock to Buy Now

    It looks like a great stock to buy now.

      Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

      Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.

        Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint

        Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies

          The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One

          The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One

            Arpita Dutt headshot

            Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit

            Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.

              Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved

              Radius Health, Inc. (RDUS) posted a wider-than-expected loss of $1.32 per share in the first quarter of 2017 which were overshadowed by the approval of Tymlos.

                Merck (MRK) Beats on Q1 Earnings & Sales, Ups Annual View

                Merck & Co., Inc. (MRK) reported first-quarter 2017 earnings of 88 cents per share, which beat the Zacks Consensus Estimate of 83 cents.

                  Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD

                  The Q1 earnings season is in full swing with financial results from 288 S&P 500 members or 63.8% of the index already out as of Apr 28, 2017.

                    Company News for April 26, 2017

                    Companies in the News are: RAD,GLW,LLY,NFLX

                      Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down

                      Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.

                        Arpita Dutt headshot

                        Key Factors to Look Out for in Celgene's (CELG) Q1 Results

                        Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.

                          Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly

                          Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly

                            What's in Store for Vertex (VRTX) this Earnings Season?

                            Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.

                              Arpita Dutt headshot

                              3 Key Factors to Look Out for in Biogen's Q1 Results

                              With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.

                                Why Eli Lilly (LLY) Might Surprise This Earnings Season

                                Eli Lilly (LLY) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

                                  S&P Global (SPGI) to Post Q1 Earnings: A Beat in the Cards?

                                  S&P Global, Inc. (SPGI) is slated to report first-quarter 2017 results on Apr 25, before the markets open.

                                    TransUnion (TRU) Q1 Earnings: What's in Store this Time?

                                    TransUnion (TRU) is scheduled to release first-quarter 2017 results before the market opens on Apr 25.

                                      Eli Lilly (LLY) Up 8.1% Since Earnings Report: Can It Continue?

                                      Eli Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS

                                        As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.

                                          CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up

                                          CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for the treatment of soft tissue sarcomas (STS).

                                            Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

                                            Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.

                                              Company News for April 18, 2017

                                              Companies in the News are: MGI,LLY,ASH,ALR,ABT

                                                5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates

                                                2017 is expected to be a strong year for drug stocks.

                                                  Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.

                                                  Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.